Sign in or create an account to add this stock to your watchlist.
About CoLucid Pharmaceuticals (NASDAQ:CLCD)
CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:CLCD
CUSIPN/A
Phone+1-781-3652596
Debt
Debt-to-Equity RatioN/A
Current Ratio11.31
Quick Ratio11.30
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-83.51%
Return on Assets-70.62%
Miscellaneous
Employees7
Outstanding Shares19,280,000
CoLucid Pharmaceuticals (NASDAQ:CLCD) Frequently Asked Questions
What is CoLucid Pharmaceuticals' stock symbol?
CoLucid Pharmaceuticals trades on the NASDAQ under the ticker symbol "CLCD."
How were CoLucid Pharmaceuticals' earnings last quarter?
CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) announced its earnings results on Wednesday, November, 9th. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.79). View CoLucid Pharmaceuticals' Earnings History.
When did CoLucid Pharmaceuticals IPO?
(CLCD) raised $55 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 5,500,000 shares at a price of $10.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and William Blair was co-manager.
Has CoLucid Pharmaceuticals been receiving favorable news coverage?
News articles about CLCD stock have trended positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. CoLucid Pharmaceuticals earned a news sentiment score of 0.25 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 45.24 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of CoLucid Pharmaceuticals?
Shares of CLCD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CoLucid Pharmaceuticals' stock price today?
One share of CLCD stock can currently be purchased for approximately $46.5250.
How big of a company is CoLucid Pharmaceuticals?
CoLucid Pharmaceuticals has a market capitalization of $895.94 million. CoLucid Pharmaceuticals employs 7 workers across the globe.
How can I contact CoLucid Pharmaceuticals?
CoLucid Pharmaceuticals' mailing address is 222 3rd St, CAMBRIDGE, MA 02142-1102, United States. The biopharmaceutical company can be reached via phone at +1-781-3652596.
MarketBeat Community Rating for CoLucid Pharmaceuticals (CLCD)
MarketBeat's community ratings are surveys of what our community members think about CoLucid Pharmaceuticals and other stocks. Vote "Outperform" if you believe CLCD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLCD will underperform the S&P 500 over the long term. You may vote once every thirty days.
CoLucid Pharmaceuticals (NASDAQ:CLCD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | N/A | N/A | N/A | Hold |
| Consensus Rating Score: | N/A | N/A | N/A | 2.25 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | $47.8333 |
| Price Target Upside: | N/A | N/A | N/A | 3.42% upside |
CoLucid Pharmaceuticals (NASDAQ:CLCD) Consensus Price Target History
CoLucid Pharmaceuticals (NASDAQ:CLCD) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
CoLucid Pharmaceuticals (NASDAQ:CLCD) Earnings History and Estimates Chart
CoLucid Pharmaceuticals (NASDAQ CLCD) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/9/2016 | 9/30/2016 | ($0.79) | ($0.79) | | | View | N/A |  |
| 8/10/2016 | Q2 | ($0.84) | ($1.06) | | | View | N/A | |
| 5/11/2016 | Q1 | ($0.7250) | ($0.85) | | | View | N/A | |
| 3/2/2016 | Q4 2015 | ($0.64) | ($0.74) | | | View | N/A | |
| 11/10/2015 | Q3 | ($0.63) | ($0.59) | | | View | N/A | |
| 8/12/2015 | Q2 2015 | ($0.40) | ($1.17) | | | View | N/A | |
| 6/18/2015 | Q1 2015 | ($0.50) | ($0.47) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
CoLucid Pharmaceuticals (NASDAQ:CLCD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
CoLucid Pharmaceuticals (NASDAQ CLCD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 64.17%
CoLucid Pharmaceuticals (NASDAQ CLCD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/5/2017 | Linda C Hogan | Insider | Sell | 2,580 | $35.18 | $90,764.40 | 718 | |
| 1/5/2017 | Thomas P Mathers | CEO | Sell | 1,502 | $34.78 | $52,239.56 | 258,021 | |
| 1/3/2017 | Bernice Kuca | Insider | Sell | 772 | $36.25 | $27,985.00 | 40,086 | |
| 1/3/2017 | Matthew D Dallas | CFO | Sell | 1,473 | $36.25 | $53,396.25 | 40,128 | |
| 12/5/2016 | Linda C Hogan | Insider | Sell | 2,583 | $37.77 | $97,559.91 | 719 | |
| 12/5/2016 | Thomas P. Mathers | CEO | Sell | 1,502 | $38.75 | $58,202.50 | | |
| 12/1/2016 | Bernice Kuca | Insider | Sell | 772 | $35.22 | $27,189.84 | | |
| 12/1/2016 | Matthew D. Dallas | CFO | Sell | 1,473 | $35.17 | $51,805.41 | | |
| 11/7/2016 | Linda C Hogan | Insider | Sell | 1,862 | $28.56 | $53,178.72 | 185 | |
| 11/7/2016 | Thomas P Mathers | CEO | Sell | 1,502 | $28.57 | $42,912.14 | 250,422 | |
| 11/1/2016 | Linda C Hogan | Insider | Sell | 719 | $30.00 | $21,570.00 | 719 | |
| 10/5/2016 | Linda C Hogan | Insider | Sell | 2,581 | $37.22 | $96,064.82 | 719 | |
| 10/5/2016 | Thomas P Mathers | CEO | Sell | 1,502 | $37.08 | $55,694.16 | 248,169 | |
| 9/14/2016 | Thomas P Mathers | CEO | Sell | 6,000 | $23.32 | $139,920.00 | 244,714 | |
| 9/9/2016 | A/S Novo | Major Shareholder | Buy | 100,000 | $20.00 | $2,000,000.00 | 3,156,563 | |
| 9/7/2016 | Thomas P Mathers | CEO | Sell | 6,502 | $21.72 | $141,223.44 | 256,916 | |
| 9/6/2016 | Linda C Hogan | Insider | Sell | 48,736 | $19.87 | $968,384.32 | 36,452 | |
| 8/31/2016 | Raymond Skwierczynski | Insider | Sell | 150 | $10.86 | $1,629.00 | 47 | |
| 8/19/2016 | Raymond Skwierczynski | Insider | Sell | 508 | $8.41 | $4,272.28 | 197 | |
| 8/10/2016 | Raymond Skwierczynski | Insider | Sell | 508 | $8.30 | $4,216.40 | 705 | |
| 8/5/2016 | Thomas P Mathers | CEO | Sell | 1,502 | $8.31 | $12,481.62 | 254,662 | |
| 8/3/2016 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 153,028 | $8.45 | $1,293,086.60 | | |
| 7/29/2016 | Raymond Skwierczynski | Insider | Sell | 508 | $9.09 | $4,617.72 | 1,213 | |
| 7/20/2016 | Raymond Skwierczynski | Insider | Sell | 508 | $8.97 | $4,556.76 | 1,721 | |
| 7/11/2016 | Raymond Skwierczynski | Insider | Sell | 508 | $9.10 | $4,622.80 | 2,229 | |
| 6/30/2016 | Raymond Skwierczynski | Insider | Sell | 516 | $7.01 | $3,617.16 | 2,737 | |
| 6/20/2016 | Raymond Skwierczynski | Insider | Sell | 1,008 | $6.80 | $6,854.40 | | |
| 6/6/2016 | Thomas P Mathers | CEO | Sell | 1,502 | $7.25 | $10,889.50 | 250,156 | |
| 4/28/2016 | Vi Associates L.P. Dp | Major Shareholder | Sell | 235 | $6.96 | $1,635.60 | | |
| 8/25/2015 | Thomas P Mathers | CEO | Buy | 7,500 | $7.10 | $53,250.00 | 7,500 | |
| 5/11/2015 | A/S Novo | Major Shareholder | Buy | 1,300,000 | $10.00 | $13,000,000.00 | | |
| 5/11/2015 | Arthur M Pappas | Director | Buy | 300,000 | $10.00 | $3,000,000.00 | | |
(Data available from 1/1/2013 forward)
CoLucid Pharmaceuticals (NASDAQ CLCD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Former CoLucid CEO Thomas P. Mathers joins Pappas Capital as Partner
www.bizjournals.com - April 10 at 9:10 AM |
 | Analyzing CoLucid Pharmaceuticals (CLCD) and Amicus Therapeutics (FOLD)
www.americanbankingnews.com - February 2 at 9:08 AM |
| Head-To-Head Review: Marinus Pharmaceuticals (MRNS) & CoLucid Pharmaceuticals (CLCD)
www.americanbankingnews.com - February 2 at 5:16 AM |
| Cambrex (CBM) & CoLucid Pharmaceuticals (CLCD) Critical Contrast
www.americanbankingnews.com - January 27 at 3:14 PM |
| Celgene (CELG) & CoLucid Pharmaceuticals (CLCD) Head to Head Review
www.americanbankingnews.com - December 30 at 7:12 PM |
| Comparing CoLucid Pharmaceuticals (CLCD) & Bristol-Myers Squibb (BMY)
www.americanbankingnews.com - December 15 at 7:10 PM |
| Comparing BioDelivery Sciences International (BDSI) & CoLucid Pharmaceuticals (CLCD)
www.americanbankingnews.com - November 23 at 1:28 PM |
| CoLucid Pharmaceuticals (CLCD) versus Female Health Company (The) (VERU) Financial Contrast
www.americanbankingnews.com - November 3 at 1:10 AM |
 | Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout
finance.yahoo.com - October 5 at 11:22 AM |
| Eli Lilly and Company -- Moody's: Eli Lilly and Company's acquisition of pipeline-stage asset is credit negative
finance.yahoo.com - October 5 at 11:22 AM |
| Here’s What You Need To Know About The Eli Lilly And Co (LLY) And CoLucid Pharmaceuticals Inc (CLCD) Deal
finance.yahoo.com - October 5 at 11:22 AM |
| Here's Why CoLucid Pharmaceuticals Inc Popped Yesterday
finance.yahoo.com - October 5 at 11:22 AM |
| Robbins Arroyo LLP: Acquisition of CoLucid Pharmaceuticals, Inc. (CLCD) by Eli Lilly and Company (LLY) May Not Be in Shareholders' Best Interests
finance.yahoo.com - October 5 at 11:22 AM |
| COLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of CoLucid Pharmaceuticals, Inc. (CLCD) Over the Proposed Sale of the Company to Eli Lilly and Company
finance.yahoo.com - October 5 at 11:22 AM |
| SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of CoLucid Pharmaceuticals, Inc. -CLCD
finance.yahoo.com - October 5 at 11:22 AM |
| SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
finance.yahoo.com - October 5 at 11:22 AM |
| Acorda Could Rival Lilly's 'Novel' Migraine Drug With Faster Onset
finance.yahoo.com - October 5 at 11:22 AM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD
finance.yahoo.com - October 5 at 11:22 AM |
| INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
finance.yahoo.com - October 5 at 11:22 AM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD
finance.yahoo.com - October 5 at 11:22 AM |
| Bragar Eagel & Squire, P.C. Is Investigating the Board of Directors of CoLucid Pharmaceuticals, Inc. (CLCD) on Behalf of Stockholders and Encourages Investors to Contact the Firm
finance.yahoo.com - October 5 at 11:22 AM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders
finance.yahoo.com - October 5 at 11:22 AM |
| Lilly Completes Acquisition of CoLucid Pharmaceuticals
finance.yahoo.com - October 5 at 11:22 AM |
| CoLucid Pharmaceuticals (CLCD) & Its Competitors Critical Comparison
www.americanbankingnews.com - October 1 at 6:30 PM |
| Reviewing Dr. Reddy's Laboratories (RDY) and CoLucid Pharmaceuticals (CLCD)
www.americanbankingnews.com - August 31 at 4:26 AM |
 | An experimental treatment for migraines just passed a critical study
www.businessinsider.com - May 12 at 9:56 PM |
 | 5 Top Technology Investments To Make In 2017
www.nasdaq.com - May 11 at 4:57 PM |
 | Eli Lilly & Co. (LLY) Completes Takeover of CoLucid Pharmaceuticals (CLCD) - StreetInsider.com
www.streetinsider.com - March 1 at 9:24 PM |
| COLUCID PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delis
biz.yahoo.com - March 1 at 9:24 PM |
 | Bragar Eagel & Squire, P.C. Is Investigating the Board …
uk.finance.yahoo.com - January 31 at 9:47 PM |
 | INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional ...
www.businesswire.com - January 30 at 10:14 PM |
| SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional ...
www.businesswire.com - January 23 at 4:37 PM |
 | SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of CoLucid ... - PR Newswire (press release)
www.prnewswire.com - January 21 at 9:26 PM |
| COLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of CoLucid Pharmaceuticals ... - PR Newswire (press release)
www.prnewswire.com - January 21 at 9:26 PM |
| CoLucid (CLCD) Alert: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in ... - PR Newswire (press release)
www.prnewswire.com - January 19 at 10:35 PM |
| Eli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M - StreetInsider.com
www.streetinsider.com - January 19 at 10:34 PM |
 | CoLucid Pharmaceuticals Inc. (CLCD) Leaped To A New High On Merger News
www.rttnews.com - January 19 at 5:33 PM |
CoLucid Pharmaceuticals (NASDAQ:CLCD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
CoLucid Pharmaceuticals (NASDAQ:CLCD) Income Statement, Balance Sheet and Cash Flow Statement
CoLucid Pharmaceuticals (NASDAQ CLCD) Stock Chart for Thursday, May, 24, 2018
Loading chart…
